Navigation Links
RNAi Helps Illuminate the Inner Workings of the Cell Cycle: Synthetic RNAissance™ Genes Created by DNA2.0 Enable Key Research
Date:11/13/2008

DNA2.0 has designed RNAi-resistant genes that enabled a breakthrough in understanding the inner workings of the cell cycle. DNA2.0's RNAissance genes are simultaneously optimized for expression in the desired host and to escape inhibition by siRNA that is targeted to the natural gene.

Menlo Park, Calif. (PRWEB) November 13, 2008 -- DNA2.0, the leading synthetic genomics company, announced today that the company's RNAissance genes had been used to shed new light on the mechanisms that ensure that each daughter cell receives a full complement of genetic material when cells divide. The study, published this week in Nature Cell Biology, was a collaboration between DNA2.0 and researchers in Dr. Jonathon Pines' group at the Wellcome/CR UK Gurdon Institute and Department of Zoology at Cambridge.

DNA2.0's RNAissance genes are widely used to ensure that phenotypes obtained when cells are treated with RNAi are not the unintended result of off-target effects. For the work reported in Nature Cell Biology, Dr. Pines went a step further. He made RNAi-resistant versions of both a wildtype and a mutated protein (Cdc20). In the mutated version, all 23 lysines found in the wildtype protein were changed to arginine, a change that prevented the mutant Cdc20 from becoming ubiquitinated. By eliminating the natural Cdc20 from cells using RNAi, the Cambridge group was able to show that ubiquitination of Cdc20 is required to prevent a cell from dividing before all of its chromosomes are lined up on the mitotic spindle. This cell cycle checkpoint is essential to prevent serious genetic damage in animals from yeast to humans.

"We were delighted to help Dr. Pines by designing and making our RNAissance genes," said Dr. Jeremy Minshull, the DNA2.0 coauthor of the study. "Making RNAi-resistant genes that encode mutant versions of cellular proteins has the potential to help us understand the molecular details of many biological processes, as Dr Pines' group has so elegantly shown."

Eliminating the natural copy of a protein and replacing it with a mutated version has previously been possible only through genetic manipulations that are largely restricted to microbial systems. Researchers now have a powerful tool to aid them in studying the molecular basis of cellular phenotypes that even allows the modification of genes and proteins that are essential for a cell's survival.

DNA2.0 is by far the most published vendor of synthetic genes, providing expert support to and collaboration with scientists in academia, government and industry. The company's RNAissance genes are enabling breakthroughs in research because they are simultaneously optimized for expression in the desired host and to escape inhibition by siRNA that is targeted to the natural gene. DNA2.0 guarantees researchers high quality synthetic genes, delivered on time, every time.

About DNA2.0
Founded in early 2003, DNA2.0 is the leading synthetic genomics company. It is the largest US provider of synthetic genes, with a global customer base comprised of academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 has provided genes to thousands of customers, for whom it has synthesized many millions of base pairs. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene synthesis process and new protein optimization technologies. The tools and applications brought to market by DNA2.0 are transforming biology into an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif. For more information, please visit www.DNA20.com.

# # #

Read the full story at http://www.prweb.com/releases/2008/11/prweb1610724.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
2. Edison Innovation Fund Helps Tris Pharma Expand
3. New Cardiology Software Helps Heart Centers Manage for Optimal Clinical Performance
4. Free White Paper Helps Biotech Laboratories Maintain a High Level of Infection Control
5. NASA technology helps predict and prevent future pandemic outbreaks
6. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
7. D-Ribose Helps Energy-Starved Hearts
8. Skin & Aging Article Finds Derma Sciences MEDIHONEY(TM) Helps to Promote Healing Where Antibiotics Fail
9. NASA Nanotechnology-Based Biosensor Helps Detect Biohazards
10. White Paper Helps Hospitals Prepare Staff for Joint Commission Environment of Care Interview Sessions
11. Derma Sciences MEDIHONEY(TM) Helps to Save Patients Limb
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)...  Vermillion, Inc. (NASDAQ: VRML ), a bio-analytical ... formation of the Steering Committee for its Pelvic Mass ... Pelvic masses can present physicians and healthcare professionals ... is ruled out, pelvic masses may include cancers of ... ovarian tumors and gastrointestinal and urinary tract masses. ...
(Date:2/11/2016)... Feb. 11, 2016  Wellcentive today announced it ... Portland, Oregon -based community care organization (CCO) ... health analytics, quality reporting and care management solutions ... its team of quality managers, analysts and care ... provider groups serving FamilyCare members. ...
(Date:2/11/2016)... 11, 2016   BioInformant announces the February ... Research Products, Opportunities, Tools, and Technologies – Market Size, ... The first and ... cell industry, BioInformant has more than a decade of ... market, by stem cell type. This powerful 175 page ...
(Date:2/10/2016)... 2016 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... that Mitsui & Co. Ltd., its partner in the ... is investing an additional CDN$25 million in the joint ... from 30% to 40%.  Mitsui will also play a ... in Sarnia , providing dedicated resources ...
Breaking Biology Technology:
(Date:2/3/2016)... -- --> --> Fourth quarter 2015: ... 1,187% compared with fourth quarter of 2014. Gross margin was ... 30.0). Earnings per share increased to SEK 6.39 (loss: 0.49). ... 74.7). , --> --> ... M (233.6), up 1,142% compared with 2014. Gross margin was ...
(Date:2/3/2016)... Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases with ... Vigilant Solutions. Brian Wenberg explains, "I ... was walking out of a convenience store and witnessed an elderly male back ... striking his vehicle and leaving the scene.  In his ...
(Date:2/2/2016)... 2016  BioMEMS devices deployed in hospitals ... medical screening and diagnostic applications, such as ... that facilitate and assure continuous monitoring without ... being bolstered through new opportunities offered by ... coupled with wireless connectivity and low power ...
Breaking Biology News(10 mins):